- Advertisement -
Neuren Pharmaceuticals (ASX: NEU), a Melbourne-based biotech that is developing therapies for neurodevelopmental disorders in early childhood, has scored a cash windfall from the US$http://www.businessnewsaustralia.com/150 million ($229 million) sale of a Rare Paediatric Disease Priority Review…
